Peter Bach

Last updated
Peter B. Bach
PeterBach.jpg
Born1964 (age 5859)
Education Harvard University
University of Minnesota
University of Chicago
Medical career
ProfessionPhysician, Health Policy Analyst, Writer
Institutions Memorial Sloan-Kettering Cancer Center
ResearchHealthcare Policy

Peter B. Bach is a physician and writer in New York City. He is the Chief Medical Officer of DELFI Diagnostics and was previously an attending and researcher at Memorial Sloan-Kettering Cancer Center where he was the Director of the Center for Health Policy and Outcomes. [1] His research focuses on healthcare policy, particularly as it relates to Medicare, racial disparities in cancer care quality, and lung cancer. Along with his scientific writings he is a frequent contributor to The New York Times and other newspapers.

Contents

Education

Bach earned a bachelor's degree in English and American Literature from Harvard University (1986), a MD from the University of Minnesota (1992) and a Masters of Arts in Public Policy (1997) from the University of Chicago. He obtained his internal medicine training at Johns Hopkins Hospital, and completed a fellowship in Pulmonary and Critical Care Medicine at the University of Chicago and Johns Hopkins Hospital.[ citation needed ]

Career

In 2021 Bach joined DELFI Diagnostics, a liquid biopsy cancer screening company, as its Chief Medical Officer in 2021. [2]

In 2012, Bach, who is a frequent critic of pharmaceutical pricing in cancer, co-authored an opinion piece in his New York Times blog outlining Memorial Sloan Kettering’s decision not to offer a new cancer drug, Zaltrap, to its patients due to the drug's price. [3] At the time, the price for Zaltrap was more than twice as high than another cancer drug already being used by the hospital to treat colorectal cancer with similar efficacy. The New York Times piece by Bach was discussed in a 60 Minutes segment highlighting the rising cost of cancer drugs. [4] Bach was seen as influential in the eventual lowering of Zaltrap's price by the manufacturer, Sanofi. [5]

In 2015, Bach released DrugAbacus, billed as an interactive tool that users can apply to model prices for cancer drugs based on a number of factors, including clinical efficacy, safety and toxicity, the value placed on a year of life, and the value of innovation. The tool then allows users to compare the generated values with existing drug prices. Additionally, Bach co-authored a paper published in the American Medical Association in which he described possible value-based drug pricing approaches in the United States. [6] [ third-party source needed ]

Bach has also worked on areas related to racial disparities within the provision of cancer care. Along with research collaborators, he has published evidence that black Medicare beneficiaries with lung cancer do not receive as high quality care as white patients. [7] [8] [9] A paper in 2007 demonstrated that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists. [10] He has worked on developing lung cancer screening guidelines also developed a lung cancer risk prediction model. [11] [12] [13] [14] He has proposed a number of strategies by which Medicare could link payment level to the value of healthcare delivered. [15] [16]

In 2016 Bach led an analysis that demonstrated that pharmaceutical companies were increasing revenues Notable policy

His lay press contributions have included op-eds on topics such as medical school tuition funding, [17] setting physician reimbursement based on market forces, [18] and why cancer screening recommendations are often not followed. [19]

Personal life

Bach chronicled his wife Ruth’s treatment for early breast cancer in a series of articles of blog posts for the New York Times , [20] and then wrote about her death from the disease in a piece for New York Magazine. [21] Bach discussed the article on Leonard Lopate's former show on WNYC. [22]

Other positions

Related Research Articles

<span class="mw-page-title-main">American Medical Association</span> United States association of physicians and medical students

The American Medical Association (AMA) is a professional association and lobbying group of physicians and medical students. Founded in 1847, it is headquartered in Chicago, Illinois. Membership was 271,660 in 2022.

Prescription drug list prices in the United States continually are among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

<span class="mw-page-title-main">Harold E. Varmus</span> American scientist (born 1939)

Harold Eliot Varmus is an American Nobel Prize-winning scientist. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.

<span class="mw-page-title-main">Preventive healthcare</span> Prevent and minimize the occurrence of diseases

Preventive healthcare, or prophylaxis, is the application of healthcare measures to prevent diseases. Disease and disability are affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices, and are dynamic processes that begin before individuals realize they are affected. Disease prevention relies on anticipatory actions that can be categorized as primal, primary, secondary, and tertiary prevention.

<span class="mw-page-title-main">Memorial Sloan Kettering Cancer Center</span> Hospital in New York City, founded 1884

Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. It was founded in 1884 as the New York Cancer Hospital. MSKCC is one of 72 National Cancer Institute-designated Comprehensive Cancer Centers. It had already been renamed and relocated, to its present site, when the Sloan-Kettering Institute for Cancer Research was founded in 1945, and built adjacent to the hospital. The two medical entities formally coordinated their operations in 1960, and formally merged as a single entity in 1980. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.

<span class="mw-page-title-main">José Baselga</span> Spanish oncologist (1959–2021)

Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.

<span class="mw-page-title-main">Lung cancer screening</span>

Lung cancer screening refers to cancer screening strategies used to identify early lung cancers before they cause symptoms, at a point where they are more likely to be curable. Lung cancer screening is critically important because of the incidence and prevalence of lung cancer. More than 235,000 new cases of lung cancer are expected in the United States in 2021 with approximately 130,000 deaths expected in 2021. In addition, at the time of diagnosis, 57% of lung cancers are discovered in advanced stages, meaning they are more widespread or aggressive cancers. Because there is a substantially higher probability of long-term survival following treatment of localized (60%) versus advanced stage (6%) lung cancer, lung cancer screening aims to diagnose the disease in the localized stage.

Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union.

Disease or patient registries are collections of secondary data related to patients with a specific diagnosis, condition, or procedure, and they play an important role in post marketing surveillance of pharmaceuticals. Registries are different from indexes in that they contain more extensive data.

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.

}}

Healthcare in the United States is largely provided by private sector healthcare facilities, and paid for by a combination of public programs, private insurance, and out-of-pocket payments. The U.S. is the only developed country without a system of universal healthcare, and a significant proportion of its population lacks health insurance.

David M. Eddy is an American physician, mathematician, and healthcare analyst who has done seminal work in mathematical modeling of diseases, clinical practice guidelines, and evidence-based medicine. Four highlights of his career have been summarized by the Institute of Medicine of the National Academy of Sciences: "more than 25 years ago, Eddy wrote the seminal paper on the role of guidelines in medical decision-making, the first Markov model applied to clinical problems, and the original criteria for coverage decisions; he was the first to use and publish the term 'evidence-based'."

Sachin H. Jain is an American physician who held leadership positions in the Center for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC). From 2015 to 2020, he served as president and chief executive officer of the CareMore Health System. In June 2020, it was announced that he would join the SCAN Group and Health Plan as its new president and CEO. He is also adjunct professor of medicine at the Stanford University School of Medicine and a Contributor at Forbes. In 2018, he was named one of American healthcare's most 100 most influential leaders by Modern Healthcare magazine (#36).

Unnecessary health care is health care provided with a higher volume or cost than is appropriate. In the United States, where health care costs are the highest as a percentage of GDP, overuse was the predominant factor in its expense, accounting for about a third of its health care spending in 2012.

The Specialty Society Relative Value Scale Update Committee or Relative Value Update Committee is a volunteer group of 31 physicians who have made highly influential recommendations on how to value a physician's work when computing health care prices in the United States' public health insurance program Medicare.

George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.

Steven Pearson is an American physician, bioethicist, and the Founder and President of the non-profit health policy and comparative effectiveness research organization Institute for Clinical and Economic Review in Boston, MA. He conducts research on cost-effectiveness analysis and healthcare technology assessment. He is also a lecturer in Harvard's Department of Population Medicine and a member of the National Institutes of Health (NIH) Comparative Effectiveness Research Steering Committee.

Carol L. Brown is the Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering Cancer Center and a professor at Weill Cornell Medical College. She is a surgeon known for her work on gynecological cancers.

Nancy Keating is an American physician who works at the Brigham and Women's Hospital and is a professor at Harvard Medical School. Her research considers the factors that influence quality care for people suffering from cancer.

References

  1. Center for Health Policy and Outcomes Memorial Sloan-Kettering Cancer Center, 2012. (Accessed 11/9/2012)
  2. Herper, Matthew (2021-06-23). "Peter Bach, industry critic, joins company aiming to make blood tests to detect cancer". STAT. Retrieved 2023-12-29.
  3. Peter B. Bach, "In Cancer Care, Cost Matters", The New York Times, 10/14/2012 (accessed 11/30/2012)
  4. Stahl, Lesley (October 5, 2014). "The cost of cancer drugs". 60 Minutes.
  5. Andrew Pollack, "Sanofi Halves Price of Cancer Drug After Sloan-Kettering Rejection", The New York Times, 11/8/2012 (accessed 11/30/2012)
  6. Bach, PB; Pearson, SD (15 December 2015). "Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs". JAMA. 314 (23): 2503–4. doi:10.1001/jama.2015.16843. PMID   26619354.
  7. Bach PB, Cramer LD, Warren JL, Begg CB (1999). "Racial differences in the treatment of early-stage lung cancer". The New England Journal of Medicine. 341 (16): 1198–205. doi: 10.1056/NEJM199910143411606 . PMID   10519898.
  8. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL (2004). "Primary care physicians who treat blacks and whites". The New England Journal of Medicine. 351 (6): 575–84. doi: 10.1056/NEJMsa040609 . PMID   15295050.
  9. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB (2002). "Survival of blacks and whites after a cancer diagnosis". JAMA. 287 (16): 2106–13. doi:10.1001/jama.287.16.2106. PMID   11966385.
  10. Pham HH, Schrag D, O'Malley AS, Wu B, Bach PB (2007). "Care patterns in Medicare and their implications for pay for performance". The New England Journal of Medicine. 356 (11): 1130–9. CiteSeerX   10.1.1.622.7686 . doi:10.1056/NEJMsa063979. PMID   17360991.
  11. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB (2003). "Variations in lung cancer risk among smokers". Journal of the National Cancer Institute. 95 (6): 470–8. doi: 10.1093/jnci/95.6.470 . PMID   12644540.
  12. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, et al. (2012). "Benefits and harms of CT screening for lung cancer: A systematic review". JAMA. 307 (22): 2418–29. doi:10.1001/jama.2012.5521. PMC   3709596 . PMID   22610500.
  13. Bach PB, Niewoehner DE, Black WC, American College of Chest Physicians (2003). "Screening for lung cancer: The guidelines". Chest. 123 (1 Suppl): 83S–88S. doi:10.1378/chest.123.1_suppl.83s. PMID   12527567.
  14. Bach PB, Silvestri GA, Hanger M, Jett JR, American College of Chest Physicians (2007). "Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 132 (3 Suppl): 69S–77S. doi:10.1378/chest.07-1349. PMID   17873161.
  15. Bach PB, Mirkin JN, Luke JJ (2011). "Episode-based payment for cancer care: A proposed pilot for Medicare". Health Affairs. 30 (3): 500–9. doi: 10.1377/hlthaff.2010.0752 . PMID   21383369.
  16. Pearson SD, Bach PB (2010). "How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement". Health Affairs. 29 (10): 1796–804. doi: 10.1377/hlthaff.2010.0623 . PMID   20921478.
  17. Peter B. Bach, "Why Medical School Should Be Free", The New York Times, 5/28/2011 (accessed 11/9/2012)
  18. Peter B. Bach, "Medicare, Start the Bidding", The New York Times, 6/3/2009. (accessed 11/9/2012)
  19. Peter B. Bach, "The Trouble With 'Doctor Knows Best'", The New York Times, 6/4/2012. (accessed 11/9/2012)
  20. Balch, Peter. "Posts published by Peter B. Bach, M.D." New York Times. Retrieved 9 May 2021.
  21. Bach, Peter (May 6, 2014). "The Day I Started Lying to Ruth". New York Magazine.
  22. "A Cancer Doctor on Losing His Wife to Cancer". Leonard Lopate Show on WNYC. May 7, 2014.
  23. CMS Seeks Methods to Appropriately Reimburse High-Quality Cancer Care Oncology NEWS International, Vol. 15 No. 2, 2/1/2006. (accessed 11/9/2012)
  24. National Cancer Policy Forum Archived 2010-03-08 at the Wayback Machine Institute of Medicine updated 9/20/2012. (accessed 11/9/2012)
  25. Report to the President: Realizing the Full Potential of Health Information Technology to Improve Healthcare for Americans PCAST, pg. 7, December, 2010. (accessed 11/9/2012)
  26. Geographic Variation in Health Care Spending and Promotion of High-Value Care Archived 2010-09-28 at the Wayback Machine Institute of Medicine updated 8/16/2012. (accessed 11/9/2012)
  27. Peter Bach World Economic Forum (accessed 11/9/2012)